Table 1 In-silico screening led to 12 candidate drugs
From: From GWAS to drug screening: repurposing antipsychotics for glioblastoma
Drug | Indication | Publication in PubMed | Clinical Trial | |
|---|---|---|---|---|
| Â | Â | Brain cancer | Other Cancers | |
Norcyclobenzaprine | Depression | Yes | NA | NA |
Protriptyline | Depression | NA | Prostate cancer | NA |
Iobenguane | Neuroblastoma | Yes | NA | Pheochromocytoma and paraganglioma: FDA approved (AZEDRA) |
Haloperidol | Schizophrenia Tourette's disorder | Yes | Pancreatic cancer | NA |
Alimemazine | Sedative | NA | Colon cancer | NA |
Nortriptyline | Depression | NA | Bladder tumor, multiple myeloma, osteosarcoma and prostate cancer | Relapsed Small Cell Carcinoma: Phase I (NCT02881125) |
Melatonin | Sleep cycle support | Yes | Pan-cancer | 30 completed clinical trials in multiple oncological indications |
Trifluoperazine | Schizophrenia | Yes | Breast cancer, colon cancer, lung cancer, lymphoma, multiple myeloma ovarian cancer and pancreatic cancer | Doxorubicin resistance cancer: Phase I/II |
Perphenazine | Schizophrenia Nausea Vomiting | Yes | Breast cancer, colon cancer, endometrial cancer, leukemia, melanoma and pancreatic cancer | NA |
Spiperone | Schizophrenia | Yes | Gastric cancer | NA |
Imipramine | Depression | Yes | Colon cancer, small cell lung cancer | Breast Cancer: Early phase I (NCT03122444) |
Levomepromazine | Psychosis Schizophrenia Bipolar disorder Nausea Insomnia | NA | Breast cancer and leukemia | NA |